Table 3.
Select Chemoimmunotherapy Trials Relevant to Untreated Young Patients With CLL
| Treatment | Phase | No. of Patients | ORR (%) | CR Rate (%) | Median PFS (months) | del(17p) Worse |
|---|---|---|---|---|---|---|
| Fludarabine → rituximab v | II | 51 | 77 | 28 | 42 | Yes |
| FR | 53 | 90 | 47 | 42 | ||
| FCR | II | 300 | 85 | 72 | 80 | Yes |
| BR | II | 117 | 88 | 23 | 33.0 | Yes |
| Pentostatin, cyclophosphamide, and rituximab | II | 64 | 91 | 41 | 32.6 | Yes |
| FC v | III | 31 | 88.4 | 21.8 | 32.8 | Yes |
| FCR | 95.1 | 44.1 | 51.8 | |||
| FCR v | III | 284 | 97.8 | 47.4 | 85% | Yes |
| BR | 280 | 97.8 | 38.1 | 78.1% |
Abbreviations: BR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; CR, complete response; FC, fludarabine plus cyclophosphosphamide; FCR, fludarabine, cyclophosphosphamide, and rituximab; FR, fludarabine plus rituximab; ORR, overall response rate; PFS, progression-free survival.